Suez, Egypt – In early 2024, Bukyline Pharmaceutical Co., Ltd. took a significant step forward by expanding its product portfolio to address a wider range of animal health needs. Building on its 2023 launch, the company introduced new offerings such as Dog Heart Guard Tablets and Camel Anti-Parasite Granules, targeting both companion animals and livestock.

This expansion was driven by customer feedback and a commitment to science-based solutions. Production Manager Mark Thompson explained, “We saw the demand for versatile, reliable medications and acted swiftly to deliver.” The new products, crafted with advanced technology and rigorous quality control, reinforced Bukyline’s reputation for excellence. By mid-2024, the expanded range had reached markets across the Middle East and beyond, solidifying Bukyline’s role as a trusted name in veterinary care. This milestone showcased the company’s ability to adapt and grow, even in its early years.